2024 QCDR	Measure	Measure	Denominator	Numerator	Denominator	Denominator	Numerator	CBF	High Priority	Measure	Includes	Inverse	Proportional	Continuous	Ratio	Number of	Risk	MIPS Reporting	Care
Measure ID	Title	Description			Exclusions	Exceptions	Exclusions	ID	Measure	Туре	Telehealth	Measure	Measure	Variable Measure	Measure	performance rates to be calculated and submitted	Adjusted	Options	Setting
	biopsy	inpatient consultation, or hospital admission for infection or sepsis within 30 days of undergoing a prostate biopsy	a prostate biopsy	Patients with urinary retention, infection or new antibiotic prescription at least 24 hours after, and within 30 days of prostate biopsy, or an inpatient consultation within 30 days of prostate biopsy, or infection or sepsis requiring hospitalization within 30 days of prostate biopsy		None	None	N/A	Yes	Outcome	No	Yes	Yes	No	No	1	No		Ambulatory Care: Clinician Office/Clinic; Hospital
		Percentage of patients who underwent repeat Shock Wave Lithotripsy within 6 months of initial procedure	an SWL procedure for the treatment of stones	Patients who underwent an ipsilateral SWL procedure within 6 months		None	None	N/A	Yes	Outcome	No	Yes	Yes	No	No	1	No		Ambulatory Care: Hospital; Ambulatory Surgical Center; Hospital; Office Based Surgery Center
		Percentage of patients with a documented urinalysis or urine culture within 14 days prior to surgical stone procedures	Patients 18 years and older who underwent a surgical procedure for the treatment of stones	Patients with documented urinalysis or urine culture within 14 days prior to surgery	None	None	None	N/A	Yes	Process	No	No	Yes	No	No	1	No	Traditional MIPS	Ambulatory Care: Clinician Office/Clinic; Outpatient Services
	Repeat Transurethral Resection of Bladder Tumor (TURBT) for T1 disease	(TURBT) within 6 weeks of the initial TURBT	clinical stage T1 bladder cancer	Patients with T1 disease who had a second TURBT within 6 weeks of the initial TURBT		Onset of systemic chemotherapy or radical cystectomy within 12 weeks of diagnosis		N/A	No	Process	No	No	Yes	No	No	1	No		Ambulatory Care: Clinician Office/Clinic; Ambulatory Care: Hospital; Ambulatory Surgical Center; Hospital
	Patients with BPH	Percentage of patients with initial diagnosis of BPH who had a creatine tab order placed or that a CT abdomen, MRI abdomen, ultrasound abdomen ordered or performed	diagnosis of BPH	A. Patients who received an order for serum creatinine laboratory testing B. Patients who received an order for diagnostic imaging tests (CT Scan, MRI, abdominal ultrasound), or had the test performed C. Patients who received an order for serum creatinne laboratory testing or diagnostic imaging tests (CT Scan, MRI, abdominal ultrasound), or tad the test performed		Patients with known renal insufficiency (CC >1.5 or documented in past medical history) or with documented fank pain, hernaturia, o urinary retention within 30 days of Initial BPH diagnosis; Patients with a urological sargical procedure within 30 days following order of SC/Imaging, with SC/Imaging war ordered following mistal BPH diagnosis; Patients with hypertensive kidney disease	r	N/A	Yes	Process	No	Yes	Yes	No	No	1	No	Traditional MIPS	Ambulatory Care: Clinician Office/Clinic; Outpatient Services
AQUA35	Non-Muscle Invasive Bladder Cancer: Initial Management/Surveillance for Non-Muscle Invasive Bladder Cancer	Percentage of patients with appropriate initial management/surveillance after initial diagnosis of non- muscle invasive bladder cancer		Patients who had 2 or more surveillance cystoscopies or who had a repeat TURBT and 1 or more surveillance cystoscopies within 14 months after initial TURBT	Noné	Onset of systemic chemotherapy or radical cystectomy within 12 weeks of bladder cancer diagnosis	None	N/A	No	Process	No	No	Yes	No	No	1	No		Ambulatory Care: Clinician Office/Clinic; Ambulatory Care: Hospital; Ambulatory Surgical Center; Hospital
	Newly Diagnosed Patients on Active	Percentage of newly diagnosed low risk patients on active surveillance who receive confirmation testing within 24 months of diagnosis		Patients who underwent a second biopsy within 24 months after date of diagnosis	None	Treatment for prostate cancer within 12 months post-diagnosis	None	N/A	No	Process	No	No	Yes	No	No	1	No	Traditional MIPS	Ambulatory Care: Clinician Office/Clinic; Ambulatory Care: Hospital; Ambulatory Surgical Center; Hospital Outpatient
		Proportion of patients newly diagnosed with low-risk prostate cancer managed with active surveillance or watchful waiting	Newly diagnosed low-risk prostate cancer patients age 30 or older	Patients on active surveillance or watchful waiting (no evidence of radical therapy post- diagnosis)		None	None	N/A	Yes	Process	No	No	Yes	No	No	1	No	Traditional MIPS	Ambulatory Care: Clinician Office/Clinic

© 2024 American Urological Association | All Rights Reserved